Allakos (FRA:37Z) Accounts Payable & Accrued Expense : €26.64 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allakos Accounts Payable & Accrued Expense?

Allakos's quarterly accounts payable & accrued expense increased from Sep. 2023 (€12.16 Mil) to Dec. 2023 (€22.03 Mil) and increased from Dec. 2023 (€22.03 Mil) to Mar. 2024 (€26.64 Mil).

Allakos's annual accounts payable & accrued expense declined from Dec. 2021 (€26.47 Mil) to Dec. 2022 (€17.73 Mil) but then increased from Dec. 2022 (€17.73 Mil) to Dec. 2023 (€22.03 Mil).

Allakos Accounts Payable & Accrued Expense Historical Data

The historical data trend for Allakos's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Accounts Payable & Accrued Expense Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

9.86

15.34

26.47

17.73

22.03

Allakos Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															20.10	15.04	12.16	22.03	26.64

Allakos Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Allakos (FRA:37Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (FRA:37Z) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALLK:USA 37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (FRA:37Z) Headlines

No Headlines